loader2
Partner With Us NRI

Company details

2,462.50
2,519.55
2,032.30
2,975.55
6M Return 11.52%
1Y Return 14.38%
Mkt Cap.(Cr) 5,539.14
Volume 1,303
Div Yield 0.08%
OI
-
OI Chg %
-
Volume 1,303

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Our Research View

Trading recommendation

Tatva Chintan Pharma Chem Ltd

Call Date

15 Jul 2021

Entry Price

-

Target Price

-

Duration

Stop Loss

-

BUY

Investment recommendation

Data not found

Rapid Results

Q1FY23 Quarterly Result Announced for Tatva Chintan Pharma Chem Ltd.

Tatva Chintan Pharma Chem Announced Q1FY23 results:

  • Consolidated (YoY Q1FY23 compared with Q1FY22):
    • Revenue from Operations for the quarter was Rs 884 million, declined by 17%
    • EBITDA (excluding other income) for the quarter was Rs 152 million, declined by 42%
    • EBIDTA Margin for the quarter was at 17% vs 25% in Q1FY22
    • Net Profit for the quarter was Rs 98 million declined by 58%
    • Net Profit Margin for the quarter was at 11% vs 22% in Q1FY22
    • Basic and Diluted EPS for the quarter was Rs 4.42 per share vs Rs 11.5 in Q1FY22

Commenting on Q1FY23 Results, Mr. Chintan Shah, Managing Director, said, "on a full year basis FY22, the total revenue was Rs 4,336 million, out of which SDA contributed Rs 2,248 million. The other three product categories viz. PTC, ES and PASC together contributed Rs 2,058 million for the whole year, so on an average the quarterly sales of these three categories put together was at Rs 515 million against this during Q1FY23 we have achieved revenue of Rs 818 million in these three product categories showing a growth of nearly 60% which clearly reflects the growth potential of PTC, ES and PASC."

 

Result PDF

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 473.09 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 7,209.51 3,450.07
LAST 3M 8,638.44 51,120.10
LAST 6M 84,196.20 -58,438.16
LAST 12M 204,915.33 -198,833.91
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
Sep 08, 2022 Dividend 20

Information

  • About Company
  • Company Info
  • Listing Info
67.57
79.17%
213.4391
25.64%
30%
Description
  • The Company was formerly incorporated as Tatva Chintan Pharma Chem Private Limited in India on 12 June 1996 under the Companies Act 2013. The status of the Company got converted from Private Limited into a Public Limited Company effective from 27 January 2021 and consequently, the name of Company also changed from `Tatva Chintan Pharma Chem Private Limited` to `Tatva Chintan Pharma Chem Limited`. The Company is promoted by Mr. Chintan Nitin Kumar Shah, Mr. Ajay Kumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani. The Company is primarily engaged in manufacturing and selling of specialty chemicals, Pharma & Agro intermediates and Quaternary Ammonium Compounds (Quats). The Company is a globally recognized specialty chemical player with several market leading products in its portfolio. Considering the wide application of products, the Company supply products to leading global companies across diverse industries, like automotive, petroleum, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care and flavor and fragrances with over 1300 customers. Apart from customers in India, the Company export products across the globe including USA, China, Germany, Japan, South Africa and UK. The Company operate through two world class manufacturing facilities located at Dahej and Ankleshwar in Gujarat both of which are strategically located very close to the Hazira Port. These units provide the Company cost and logistics advantage and enabling seamless export and import operations. The Company`s manufacturing facilities obtained ISO 9001:2015 and 14001:2015 certification for robust quality management systems. Employing modern equipment like reactors, assembly lines, ANFDs, centrifuges and RCVDs, enabled the Company to undertake multiple chemistry process. The Company successfully established an integrated model comprising world class manufacturing infrastructure, complex & chemical processes, warehousing facilities and technically sound R&D capabilities, which enables to achieve high operational efficiency and quality, to innovate & customize and to ensure sustainable operations with wide offerings. The Company has sophisticated quality control lab equipped with modern analytical equipment, enabling it to detect impurities upto PPM levels and achieve `ultra-pure`grade certification. The Company Promoters identified an opportunity in manufacturing Phase Transfer Catalyst (PTC), which is a niche segment within the specialty chemicals space. With PTC as the base, the Company have marked presence in the entire value chain including PTC, Structure Directing Agents (SDA), Electrolyte Salts (ES) and Pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The Company have a dedicated Department of Scientific and Industrial Research (DSIR) approved R&D centre at its Vadodara facility where qualified and experienced in-house R&D team focus on development of new products and improvement in current manufacturing processes. The Company is having modern systems and analytical development laboratory with state-of-the-art instrumentation. In 2004, the Company received licence from the FDA, Gujarat at its Ankleshwar manufacturing plant. In 2007, the Company commenced Ankleshwar manufacturing facility and increased the expansion of manufacturing capacity. In 2011, the Company started commercial manufacturing of Structure Directing Agents (SDA). In 2015, the Company was accredited Appreciation Certificate for the Ankleshwar Plant from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for its contribution to revenue and voluntary compliance with tax laws. The Company achieved revenue of nearly Rs 1 bn. The Company established a warehousing plant in The Netherlands. Tatva Chintan USA Inc. was incorporated as a wholly owned Subsidiary of TCPCL. In 2016, the Company was accorded the status of a two-star export house for the Ankleshwar plant from the Directorate General of Foreign Trade (DGFT), Ministry of Commerce and Industry (MoCI), Government of India (GoI). In 2017, manufacturing plant was established in Dahej, Gujarat. In 2018, the R&D facility was set up in Vadodara. Tatva Chintan Europe BV, was incorporated as wholly owned Subsidiary of the Company in year 2019. In FY 2019-20, the Company`s Ankleshwar unit was converted to a zero liquid effluent discharge facility. The products proved efficiency to ensure lower by-products and waste generation in chemical processes. Additionally, the Company participated in the ` Together for Sustainability` initiatives whereby sustainability sourcing practices of chemical suppliers, like ecological and social aspects were assessed. Under this initiative, the Company involved Ecovadis to audit sustainability practices and performance, the results of which were above the industry average. This created a robust initiative and focused on retaining key customers who consider sustainability an important parameter to do business. In 2020, the Company achieved another Rs 2 billion revenue. In 2021, the manufacturing capacity at Dahej facility in Gujarat increased giving rise to aggregate installed reactor manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines respectively. During the year 2021, the Company had issued 12,052,500 Equity Shares as Bonus Shares to all the existing shareholders of the Company in the ratio of 1.5:1 vide Board Resolution dated 03 March 2021 which was passed pursuant to passing of Special Resolution by Shareholders in ExtraOrdinary General Meeting held on 27 January 2021 against existing 8,035,000 Equity Shares.

Read More

No Data Found

AGM Date (Month) : Oct
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 543321
NSE Code : TATVA
Book Closure Date (Month) :
BSE Group : A
ISIN : INE0GK401011

ICICIdirect Tatva Chintan Pharma Chem Ltd FAQ

You can buy Tatva Chintan Pharma Chem Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Tatva Chintan Pharma Chem Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 28, 2022 02:59 PM the closing price of Tatva Chintan Pharma Chem Ltd was ₹ 2,499.05.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 28, 2022 02:59 PM, the market cap of Tatva Chintan Pharma Chem Ltd stood at ₹ 5,539.14.
The latest PE ratio of Tatva Chintan Pharma Chem Ltd as of Sep 28, 2022 02:59 PM is 67.57
The latest PB ratio of Tatva Chintan Pharma Chem Ltd as of Sep 28, 2022 02:59 PM is 0.08
The 52-week high of Tatva Chintan Pharma Chem Ltd is ₹ 2,975.55 while the 52-week low is ₹ 2,032.30 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE